The 5 mg/mL concentration is the most widely used across telehealth platforms
However, key catalysts are imminent : - Q3 2025 : Retatrutide's Phase 2b renal safety data (critical for long-term use)
EveryCRSReport.com, accessed December 19, 2025, Major Update on GLP-1 Litigation involving Compounding Pharmacies, accessed December 19, 2025, Eli Lillys Legal Battle with Empower Raises Questions for the Compounding Pharmacy Market Towards Healthcare, accessed December 19, 2025, Eli Lilly Strikes Back Against Pharmacy Compounders and Telehealth Platforms | Insights, accessed December 19, 2025, Novo Nordisk, Inc
While common side effects such as mild redness, swelling, and tenderness may occur, they are generally temporary and manageable